Article
Treating dyslipidemia in the high-risk patient
- Author:
- Peter H. Jones, MD
How low should LDL levels be pushed and how important are other lipoproteins in our efforts to reduce CV risk? Here’s an update.
Article
Safety of statins: Effects on muscle and the liver
- Author:
- Abu R. Vasudevan, MBBS, MD, MRCP
- Yasmin S. Hamirani, MBBS
- Peter H. Jones, MD
Hepatotoxicity and myopathy are uncommon but worrisome. ALT and AST should be measured at baseline and periodically during statin therapy.
Article
Statins: The case for higher, individualized starting doses
- Author:
- Peter H. Jones, MD
We’re not getting our patients’ low-density lipoprotein cholesterol down to goal levels. We would do better by starting at a higher dose if the...
Article
Lipid-lowering: Can ezetimibe help close the treatment gap?
- Author:
- Ryan C. Neal, MD
- Peter H. Jones, MD
Ezetimibe (Zetia) is an important new drug for lowering cholesterol and may help overcome some of the barriers.